Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D

Osteoporosis International

Volumn 24, Issue 10, 2013, Pages 2571-2579

  Alibhai, S M H ^a,b,c,d   Mohamedali, H Z ^a   Gulamhusein, H ^a   Panju, A H ^a   Breunis, H ^a   Timilshina, N ^a   Fleshner, N ^a   Krahn, M D ^a,c,d   Naglie, G ^c,d,e   Tannock, I F ^a,c,d   Tomlinson, G ^a,f   Warde, P ^g   Duff Canning, S ^a   Cheung, A M ^a,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ROTMAN RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Androgen deprivation therapy; Bone mineral density; Calcium; Osteoporosis; Prostate cancer; Side effects; Vitamin D

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GONADORELIN AGONIST; VITAMIN D;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; COGNITION; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FRACTURE; HUMAN; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMUR NECK; FOLLOW-UP STUDIES; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; VITAMIN D;

EID: 84885428457     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2343-4     Document Type: Article

References (34)

1. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR (2002) Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60:7-11, discussion 11-12
2. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238-244
3. Alibhai SM, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60:201-215
4. Alibhai SMH, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, Krahn M, Fleshner NE, Warde P, Duff Canning S, Klotz L, Naglie G (2010) Impact of androgen-deprivation therapy on physical function and quality of life in men with non-metastatic prostate cancer. J Clin Oncol 28:5038-5045
5. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164
6. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27:3452-3458
7. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005-1007
8. Kiratli BJ, Srinivas S, Perkash I, Terris MK (2001) Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57:127-132
9. Wadhwa VK, Weston R, Mistry R, Parr NJ (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104:800-805
10. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endo Metab 90:6410-6417
11. Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2006) Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 175:1679-1683, discussion 1683
12. Duncan GG, Corbett T, Lukka H, Warde P, Pickles T (2006) GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 13:2962-2966
13. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endo Metab 97:1802-1822
14. Datta M, Schwartz GG (2012) Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist 17:1171-1179
15. Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, Raventos CX (2007) The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int 99:812-815, discussion 815-816
16. Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT (2007) Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70:122-126
17. Alibhai SMH, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock I, Naglie G, Tomlinson G, Fleshner N, Warde P, Duff Canning S (2010) Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol 38:5030-5037
18. Khan AA, Brown J, Faulkner K, Kendler D, Lentle B, Leslie W, Miller PD, Nicholson L, Olszynski WP, Watts NB (2002) Standards and guidelines for performing central dual X-ray densitometry from the Canadian Panel of International Society for Clinical Densitometry. Journal of Clinical Densitometry 5:435-445
19. Hui SL, Gao S, Zhou XH, Johnston CC Jr, Lu Y, Gluer CC, Grampp S, Genant H (1997) Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res 12:1463-1470
20. Lu Y, Fuerst T, Hui S, Genant HK (2001) Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int 12:438-444
21. Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE (2012) Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 13:275-284
22. Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43-46
23. Morote J, Planas J, Mir MC, Raventos CX, Encabo G, Doll A (2011) 33% radius evaluation to assess bone mineral density in prostate cancer patients. World J Urol
24. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L (2010) Fracture Types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 Men. J Urol 184:918-924
25. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181-186
26. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755
27. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS (2010) Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 184:1316-1321
28. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA (2011) Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 155:827-838
29. Bischoff-Ferrari HA, Dawson-Hughes B, Baron JA, Burckhardt P, Li R, Spiegelman D, Specker B, Orav JE, Wong JB, Staehelin HB, O'Reilly E, Kiel DP, Willett WC (2007) Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr 86:1780-1790
30. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR (2011) Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 342:d2040
31. Gao X, LaValley MP, Tucker KL (2005) Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 97:1768-1777
32. Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, Flicker L, Wark J, Jackson RD, Cauley JA, Meyer HE, Pfeifer M, Sanders KM, Stahelin HB, Theiler R, Dawson-Hughes B (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367:40-49
33. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339:b3692
34. Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, Minisola S, Rossini M (2009) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 20:239-244